Save time and jump to the most important pieces.
SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)
SC 13G - Barinthus Biotherapeutics plc. (0001828185) (Subject)
OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his experience spearheading clinical studies from early development through late-stage trials, he is a valuable addition to the Barinthus Bio team during a critical time in our growth," said Chi
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), today announced the most significant data so far from the ongoing Phase 2b HBV003 clinical trial. The data will be presented by Dr. Chun-Jen Liu as an oral presentation on November 18, 2024, at 17:30 PT at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that gu
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus infection, and Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company dev
OXFORD, United Kingdom, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, today announced that updated clinical data from its chronic hepatitis B program will be highlighted as a late breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024 being held November 15-19, 2024 in San Diego, California and attendance at multiple conferences in November: Medical Congresses AASLD – The Liver Meeting® 2024: Late breaking abstract accepted as oral presentation.Title: VTP-300 comb
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
3 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, provided an overview of the Company's progress and announced its financial results for the second quarter of 2024. "Following the positive VTP-300 Phase 2 data in hepatitis B virus (HBV) in the second quarter, we made the strategic decision to prioritize our HBV and celiac disease programs. These two programs have the greatest probability for success and value creation, and represent significant opportunities in therapeutic areas with substantial unmet patient need," said Bill Enright, Chief
OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company's progress. "So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect
OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company's progress. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. "2023 was a productive year for Barinthus Bio, with data presented in our HBV and HPV programs, the first patient visit in our next generation prostate cancer program and up to $35 million of future funding committed from the Coalition for
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f
Barclays analyst Carter Gould maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Overweight and lowers the price target from $7 to $3.
The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized.The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an estimated extension to the cash runway into the second quarter of 2026.